Exelixis Zanzalintinib-Atezolizumab Moves Forward on PDUFA Calendar with FDA NDA Acceptance

Exelixis announced a major milestone for its colorectal cancer treatment program as the U.S. Food and Drug Administration accepted the New Drug Application for zanzalintinib in combination with atezolizumab. The regulatory approval schedule places this dual-therapy candidate on the PDUFA calendar with a target action date of December 3, 2026, marking a key entry point for the combination therapy in the oncology market.

Phase 3 STELLAR-303 Trial Provides Clinical Foundation

The FDA’s decision to proceed with the standard review pathway reflects positive efficacy data from the Phase 3 STELLAR-303 pivotal trial. This combination approach targets a specific patient population: adults with metastatic colorectal cancer who have exhausted standard chemotherapy options including fluoropyrimidine, oxaliplatin, and irinotecan-based regimens. For patients with RAS wild-type tumors, prior exposure to anti-epidermal growth factor receptor therapy must also have occurred, establishing a well-defined treatment-resistant group where the combination shows therapeutic potential.

Understanding the PDUFA Calendar Timeline

The December 2026 PDUFA calendar target represents approximately nine months from the current review start point. This standard review pathway allows the FDA sufficient time to thoroughly evaluate clinical safety and efficacy data from the STELLAR-303 trial before making a final approval decision. The PDUFA calendar designation provides both Exelixis and the medical community with clear visibility into the potential market availability timing for this treatment option.

Market Reception and Regulatory Momentum

Exelixis shares showed positive momentum following the announcement, rising 0.75 percent to $41.67 in pre-market trading, reflecting investor confidence in the regulatory process. Dana Aftab, Executive Vice President of Research and Development at Exelixis, expressed enthusiasm about the FDA collaboration throughout the review process, highlighting the significance of seeing the first zanzalintinib NDA advance through the formal regulatory evaluation system. As the PDUFA calendar moves toward the end of 2026, the company’s ability to navigate FDA feedback will become increasingly important for achieving the targeted approval date.